Sagent Pharmaceuticals Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Sagent Pharmaceuticals Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile


  • Products Id :- GDPH139075D
  • |
  • Pages: 25
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Sagent Pharmaceuticals Inc (Sagent), formerly Sagent Holding Co, a subsidiary of Nichi-Iko Pharmaceutical Co Ltd, is a biopharmaceutical company that develops and manufactures injectable products. The company offers products such as amikacin sulfate injection, USP, ampicillin and sulbactam for injection, ampicillin for injection, USP, azithromycin for injection, cefazolin for injection, USP, cefepime for injection, acetazolamide for injection, and adenosine injection. It also offers busulfan injection and pentobarbital sodium injection, USP. The company provides its products in injection and oral dosage forms. It markets its products across the US. Sagent is headquartered in Schaumburg, Illinois, the US.

Sagent Pharmaceuticals Inc-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Sagent Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Sagent Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Sagent Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Sagent Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Sagent Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10

Sagent Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Sagent Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 12

Asset Purchase 12

Sagent Pharma Acquires Product Portfolio from Teva Pharma and Actavis for USD40 Million 12

Equity Offering 13

Sagent Pharma Completes Public Offering Of Shares For USD 75.3 Million 13

Acquisition 15

Nichi-iko Pharma Acquires Sagent Pharma for USD734.2 Million in Tender Offer 15

Hong Kong King-Friend Pharmaceutical Acquires 100% Stake in Sagent (China) Pharma From Sagent Pharma 17

Sagent Pharma Acquires Omega Labs for USD85.3 Million 18

Zhejiang Hisun Pharma Plans to Divest Stake in Sagent Pharma 20

Sagent Pharma Acquires Remaining 50% JV Stake in Kanghong Sagent from Chengdu Kanghong Pharma for USD25 Million 21

Sagent Pharmaceuticals Inc-Key Competitors 22

Sagent Pharmaceuticals Inc-Key Employees 23

Sagent Pharmaceuticals Inc-Locations And Subsidiaries 24

Head Office 24

Other Locations & Subsidiaries 24

Joint Venture 24

Appendix 25

Methodology 25

About GlobalData 25

Contact Us 25

Disclaimer 25

List of Figures

Sagent Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Sagent Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Sagent Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Sagent Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Sagent Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Sagent Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Sagent Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Sagent Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Sagent Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10

List of Tables

Sagent Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts 2

Sagent Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Sagent Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Sagent Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Sagent Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 8

Sagent Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10

Sagent Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Sagent Pharma Acquires Product Portfolio from Teva Pharma and Actavis for USD40 Million 12

Sagent Pharma Completes Public Offering Of Shares For USD 75.3 Million 13

Nichi-iko Pharma Acquires Sagent Pharma for USD734.2 Million in Tender Offer 15

Hong Kong King-Friend Pharmaceutical Acquires 100% Stake in Sagent (China) Pharma From Sagent Pharma 17

Sagent Pharma Acquires Omega Labs for USD85.3 Million 18

Zhejiang Hisun Pharma Plans to Divest Stake in Sagent Pharma 20

Sagent Pharma Acquires Remaining 50% JV Stake in Kanghong Sagent from Chengdu Kanghong Pharma for USD25 Million 21

Sagent Pharmaceuticals Inc, Key Competitors 22

Sagent Pharmaceuticals Inc, Key Employees 23

Sagent Pharmaceuticals Inc, Subsidiaries 24

Sagent Pharmaceuticals Inc, Joint Venture 24

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Sagent Pharmaceuticals Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license
Single User License
USD 250 INR 17743
Site License
USD 500 INR 35485
Corporate User License
USD 750 INR 53228

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com